From this page You could reach all the figures at the Turkish Journal of Hematology archive.
You could save all the imges by the save as button and paste them to office documents.
Please use the articles details for reference.
You could see the abstracts of the images from the link above the image.
Search In Pictures
Search In Articles
Not null!
Search term(s) must be at least 3 characters!
All Types
Microscope display
FISH display
(MDCT),MRI,radiologic
Dermatologic
Other
13 records found...
Spontaneous Subdural Hematoma Associated with Kasabach-Merritt Syndrome: A Case Report
Figure : The cranial magnetic resonance imaging revealed bilateral subacute subdural haematomas in the frontotemporoparietal region on axial T2-weighted image (a), T1-weighted (b), FLAIR image (c) respectively.
HbA2-Yokoshima (delta 25(B7)Gly >Asp) and Hb A2-Yialousa (delta 27(B9)Ala>Ser) in Turkey
Figure 1: DNA sequencing of the HbA2-Yokoshima (a) and HbA2-Yialousa (b) cases.
Cerebellar Granulocytic Sarcoma: A Case Report
Figure 1: Hemangiomas and cushingoid appearance (pre-treatment).
Successful Treatment with Propranolol in a Patient with a Segmental Hemangioma: A Case Report
Figure 2: Hemangiomas on the face following propranolol treatment.
Acute Effects of 17ß-Estradiol and ATP on Endothelial Cells; Effects of Genistein and PMA on Calcium Response
Figure 1. Effect of E2 and ATP application on (Ca+2)i of HUVEC. Tracings showing the changes in (Ca+2)i of HUVEC evoked by application of 10 µM E2 and 100 µM ATP. Cultures were deprived of E2 for 48 hours. Fluorescence was recorded from fura-2 loaded monolayers grown on glass coverslips, at room temperature in HBS containing 0.1% BSA, 1.8 mM CaCl2, pH 7.4. Tracings represent the mean of increases in (Ca+2)i obtained from 6 experiments.
Acute Effects of 17ß-Estradiol and ATP on Endothelial Cells; Effects of Genistein and PMA on Calcium Response
Figure 2. Anion-exchange elution profiles of lysates from myo-[2-3H]inositol prelabelled HUVEC: Cells were incubated with only 10 µL ethanol (basal) or 10 µM estradiol or genistein + estradiol for 5 minutes. Cell lysates were applied to Dowex-1 columns. After washing out myo-(2-3H) inositol with water, (3H) inositolphosphates were eluted with stepwise addition of solutions containing increasing amounts of formate. Elution profile exibits 4 distinct peaks corresponding to glycerophosphoinositol (GroIP), inositol-1-phosphate (IP), inositolbisphosphate (IP2), inositoltrisphosphate (IP3) and demonstrates that treatment of endothelial cells with E2 increases phosphoinositide formation.
Acute Effects of 17ß-Estradiol and ATP on Endothelial Cells; Effects of Genistein and PMA on Calcium Response
Figure 3. (3H) Inositol labelled endothelial cells were stimulated for 5 minutes with E2 or E2 vehicle ethanol (basal) or with E2 after incubation with genistein. Cells were lyzed and applied to Dowex-1 columns. After washing out (3H) inositol with water, total inositolphosphates were eluted by addition of 1 M ammonium formate/0.1 M formic acid. Radioactivity in eluates was measured by liquid scintillation counting. The results (mean ± SEM of 4 seperate experiments) show the percent increases in total inositolphosphates. The graph demonstrates that E2 causes 45% increase in phoshoinositide turnover which can be significantly inhibited by genistein pretreatment in HUVEC
Acute Effects of 17ß-Estradiol and ATP on Endothelial Cells; Effects of Genistein and PMA on Calcium Response
Figure 4. The role of tyrosine phosphorylation in E2- stimulated signaling pathway in HUVEC. The tracing demonstrates that genistein attenuates the peak increase in (Ca+2)i evoked by E2 and ATP 75% and 62% respectively compared to controls and markedly decreases the second phase of ATP response. The tracing represent the mean of data obtained from 4 experiments. Cells were treated with 100 µM genistein for 12 minutes before stimulation with E2 (10 µM) and ATP (100 µM). After genistein treatment E2 vehicle ethanol caused nearly 20% increase in (Ca+2)i. The extracellular Ca+2 concentration was 1.8 mM during the experiments.
Acute Effects of 17ß-Estradiol and ATP on Endothelial Cells; Effects of Genistein and PMA on Calcium Response
Figure 5. The role of PKC on E2-evoked Ca+2 response in HUVEC. Tracing demonstrates that PMA attenuates the peak increase in (Ca+2)i stimulated by E2 and ATP compared to controls as shown in Figure 1. E2- deprived HUVEC were incubated with 100 nM PMA for 2.5 hours before stimulation with E2 (10 µM) and ATP (100 µM). Tracing represent the mean of data obtained in 9 experiments.
Effect of Sialic Acid on Platelet Cryopreservation
Figure 1. Effect of different concentrations of sialic acid (SA) on, P-selectin and glycoprotein Ib expression, ADP and ristosetin-induced platelet aggregation, ADP-induced P-selectin (A-P-selectin) and glycoprotein Ib (A-GP Ib/IX) expression.
1
2
Next Page >
Last Page >>
Sayfa 1 / 2 -- Toplam Kayıt 13 -- Listelenen kayıt sayısı 10
Not null!
Search term(s) must be at least 3 characters!
All Columns
Referance Numbers
Titles
Summeries
Keywords
0 records found...
1
Sayfa 1 / 1 -- Toplam Kayıt 0 -- Listelenen kayıt sayısı 0
AUTOIMMUNE DISORDERS (0 / 0)
Autoimmune Hemolytic Anemias (0 / 0)
Others (0 / 0)
CHEMOKINES (0 / 8)
Chemokines and cytokines (0 / 0)
Chemotactic Effects (0 / 2)
Other Effects (0 / 0)
Hematopoietic (0 / 0)
Angiogenic (0 / 0)
HIV Effects (0 / 6)
Regulation of Receptor Expression (0 / 0)
Signal Transduction (0 / 0)
CYTOGENETICS (0 / 2)
Gene Polymorphisms (0 / 2)
HEMOSTASIS (0 / 87)
Platelet and the vessel wall (0 / 13)
Blood coagulation (0 / 24)
Biology of hemostatic proteins (0 / 4)
Fibrinogen (0 / 0)
Vitamin K-dependent coagulation factors (0 / 0)
Coagulation factors (0 / 4)
Factor VIII-Factor IX-Factor XI (0 / 8)
Other coagulation factors (0 / 0)
Protein C anticoagulant pathway (0 / 0)
Other coagulation inhibitors (0 / 0)
Fibrinolytic enzymes and inhibitors (0 / 0)
Thrombotic Disorders (0 / 36)
Inherited coagulopathies (0 / 4)
Antithrombin deficiency (0 / 0)
Protein C deficiency (0 / 4)
Protein S deficiency (0 / 0)
Factor V Leiden mutation (0 / 0)
Prothrombin t20210A Mutation (0 / 0)
Acquired coagulation disorders (0 / 5)
Disseminated intravascular coagulation (0 / 5)
Liver Disease (0 / 0)
Vitamin K Deficiency (0 / 0)
Massive Transfusion Coagulapathies (0 / 0)
Acquired Inhibitors of coagulation proteins (0 / 0)
Replacement therapies (0 / 0)
Other therapies (0 / 0)
Cancer and thrombosis (0 / 3)
Antiphospholipid antibody syndrome (0 / 1)
Thrombotic thrombocytopenic purpura (0 / 1)
Heparin-induced thrombocytopenia (0 / 0)
Venous thromboembolism treatment (0 / 0)
Arterial thrombosis (0 / 13)
Antithrombotic therapy (0 / 6)
Heparin, low molecular weight heparin (0 / 3)
Direct thrombin inhibitors (0 / 0)
Oral anticoagulants (0 / 3)
Antifibrinolytic therapy (0 / 0)
Endothelium (0 / 1)
HEMATOLOGİC MANIFESTATİONS OF SYSTEMİC DISEASES (0 / 46)
GENE THERAPY (0 / 0)
HEMATOPOIESIS (0 / 8)
Stem and Primitive Progenitor Cells (0 / 0)
Red Blood Cells (0 / 0)
Granulocytes (0 / 1)
Lymphocytes (0 / 3)
Monocytes (0 / 0)
Eosinophilia (0 / 1)
Basophilia (0 / 0)
Megakaryocytes (0 / 3)
Mast Cells (0 / 0)
IRON (0 / 13)
Iron Deficiency (0 / 10)
Iron Overload (0 / 3)
IMMUNOLOGY (0 / 22)
Innate Immunity (0 / 0)
Immunoglobulins (0 / 16)
Antigen Recognition by T Lymphocytes (0 / 0)
The Development of B Lymphocytes (0 / 0)
T-Cell Mediated Immunity (0 / 0)
The Humoral Immune Response (0 / 0)
Immundeficiency dieases (0 / 0)
Allergy and Hypersensitivity (0 / 3)
Immune Response Disorder (0 / 3)
Autoimmunity: responses to self antigens (0 / 2)
Transplant rejection: responses to alloantigens (0 / 0)
Tumor immunology (0 / 0)
Lymphoid Cells Neoplasms (0 / 0)
B-cell neoplasms (0 / 0)
T-cell neoplasms (0 / 0)
NK cell neoplasms (0 / 0)
Others (0 / 0)
INFECTION (0 / 16)
Febril Neutropenia (0 / 6)
Viral Infections (0 / 1)
Fungan Infections (0 / 1)
Bacterial Infections (0 / 2)
Parasitic Infections (0 / 2)
MARROW (0 / 9)
Physiology of Hematopoiesis (0 / 5)
Bone Marrow Failure (0 / 1)
Acquired Aplastic Anemia (0 / 3)
Fanconi Anemia (0 / 0)
Inherited Pure Red Cell Anemia (0 / 0)
Acquired Pure Red Cell Anemia (0 / 0)
STEM CELL TRANSPLANTATION (0 / 54)
Stem cell physiology (0 / 9)
Stem cell mobilization (0 / 0)
Immunologic tolerance (0 / 0)
Graft rejection (0 / 0)
Conditioning regimen (0 / 0)
Allo transplantation (0 / 18)
Auto transplantation (0 / 2)
Non myeloablative (0 / 0)
Organ Specific Toxicity (0 / 3)
Clinical Care of Graft-Versus-Host Disease (0 / 10)
Acute GVHD (0 / 0)
Chronic GVHD (0 / 10)
NEOPLASIA (0 / 354)
Pediatric hematologic Malignancies (0 / 3)
Pediatric Leukemia (0 / 8)
Pediatric Lymphomas (0 / 2)
Acute Leukemia (0 / 12)
Acute Lymphoblastic Leukemia (0 / 36)
Acute Myeloblastic Leukemia (0 / 66)
Myelodysplastic Syndromes (0 / 3)
Chronic Leukemia (0 / 0)
Chronic Lymphocytic Leukemia (0 / 7)
Chronic Myeloid Leukemia (0 / 18)
Other Lymphoproliferative Disorders (0 / 2)
Other Leukemias (0 / 12)
Lymphomas (0 / 37)
Hodgkin Lymphoma (0 / 10)
Non Hodgkin Lymphoma (0 / 45)
Chronic Myeloproliferative Neoplasms (0 / 32)
Pharmacotherapeutics (0 / 3)
Oncogenes (0 / 0)
Multipl myeloma (0 / 45)
Plasmacytoma (0 / 2)
Cryoglobulinemia (0 / 2)
Plasma Cell Disorders (0 / 7)
PHAGOCYTES (0 / 16)
Neutrophils (0 / 4)
Monocytes and Macrophages (0 / 3)
Eosinophils (0 / 3)
Basophils (0 / 0)
Mast cells (0 / 0)
Dendritic cells (0 / 6)
Chemotaxis (0 / 0)
Antigen presentation (0 / 0)
Phagocytosis, cytotoxicity (0 / 2)
PLATELETS (0 / 34)
Physiology of Normal Platelets (0 / 10)
Signal Transduction (0 / 0)
Disorders of Platelets (0 / 12)
von Willebrand Disease (0 / 7)
Acquired Platelet Disorders (0 / 0)
Autoimmune and Alloimmune platelet disorders (0 / 2)
RED CELLS (2 / 92)
Hemoglobin disorders (0 / 6)
Anemia (2 / 40)
Nutritional anemia (0 / 9)
iron, cobalamin, folate deficiency (0 / 7)
Fanconi Anemia (0 / 1)
Aplastic Anemia (0 / 6)
Myeloproliferative and myelodysplasia (0 / 0)
Immune Hemolytic anemias (2 / 12)
Red cell membrane disorders (0 / 7)
Paroxymal Nocturnal hemoglobin (PNH) (0 / 0)
Enzyme disorders (0 / 0)
Sickle cell anemia (0 / 4)
Thalassemia (0 / 19)
Other hemoglobinopathies (0 / 11)
Polycythemia (0 / 4)
Polycythemia Vera (0 / 3)
Secondary Polycythemia (0 / 0)
WHITE CELLS (0 / 4)
Congenital Neutropenia (0 / 3)
Acquired Neutropenia (0 / 0)
Leucocyte Function Disorders (0 / 0)
Lymphocytes (0 / 0)
SUPPORTIVE CARE (0 / 0)
MOLECULAR HEMATOLOGY (0 / 6)
TRANSFUSION MEDICINE (0 / 10)
Apheresis (0 / 4)
Red Blood Cells (0 / 3)
White cell transfusions (0 / 1)
Platelet transfusions (0 / 0)
VASCULAR BIOLOGY (0 / 0)
OTHER (325 / 85)
FLOW CYTOMETRY (0 / 2)
STORAGE DISORDERS (0 / 14)
Spleen (0 / 1)
Experimental Hematology (0 / 3)
IRRADIATION (0 / 3)
Copyright © 2024 Atlas of Hematology. All rights reserved.
LookUs
&
OnlineMakale